RAS Mutation Associated with Short Surgically Controllable Period in Colorectal Liver Metastases: a Retrospective Study

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2024 Sep 12

PMID 39267117

Authors

Sono Ito

Takeshi Takamoto

Satoshi Nara

Daisuke Ban

Takahiro Mizui

Hiroshi Nagata

Yasuyuki Takamizawa

Konosuke Moritani

Shunsuke Tsukamoto

Yukihide Kanemitsu

Yusuke Kinugasa

Minoru Esaki

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic implications of the RAS status in colorectal cancer liver metastasis (CRLM) remain unclear. This study investigated the prognostic significance of RAS status after curative hepatectomy, focusing on surgical controllability.

Methods: This retrospective study included liver-only CRLM patients who underwent the first hepatectomy between 2015 and 2022 at the National Cancer Center Hospital. Recurrence-free survival (RFS), surgically controllable period (SCP), and overall survival (OS) were compared between RAS wild-type (RAS-wt) and mutant (RAS-mt) patients. Multivariate analyses were conducted to identify independent prognostic factors for each outcome and independent risk factors for less than 1 year SCP.

Results: A total of 150 patients were evaluated, comprising 63 patients with RAS-mt status. There was no significant difference in RFS between RAS-mt and RAS-wt (7.00 vs. 8.03 months, p = 0.48). RAS-mt patients exhibited worse SCP (11.80 vs.21.13 months, p < 0.001) and OS (44.03 vs. 70.03 months, p < 0.001) compared to RAS-wt. Multivariate analysis identified RAS-mt as an independent prognostic factor for both OS (hazard ratio [HR]: 3.37, p < 0.001) and SCP (HR: 2.20, p < 0.001), and as an independent risk factor for less than 1 year of SCP (odds ratio, 2.31; p = 0.03).

Conclusions: CRLM with RAS mutations should be considered for strict surgical indications with preoperative chemotherapy and thorough examination, considering the possibility of short SCP.

References

Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J . Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012; 30(24):2956-62. PMC: 3417049. DOI: 10.1200/JCO.2011.38.2994. View

Vauthey J, Zimmitti G, Kopetz S, Shindoh J, Chen S, Andreou A . RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013; 258(4):619-26. PMC: 3856211. DOI: 10.1097/SLA.0b013e3182a5025a. View

Margonis G, Amini N, Andreatos N, Sasaki K, McVey J, Mirza M . KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases. HPB (Oxford). 2019; 21(11):1527-1534. DOI: 10.1016/j.hpb.2019.03.368. View

Brudvik K, Jones R, Giuliante F, Shindoh J, Passot G, Chung M . RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases. Ann Surg. 2017; 269(1):120-126. DOI: 10.1097/SLA.0000000000002319. View

Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T . Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 2000; 231(4):487-99. PMC: 1421023. DOI: 10.1097/00000658-200004000-00006. View

Su Y, Liu W, Yan X, Wang L, Liu M, Wang H . Five-year survival post hepatectomy for colorectal liver metastases in a real-world Chinese cohort: Recurrence patterns and prediction for potential cure. Cancer Med. 2023; 12(8):9559-9569. PMC: 10166917. DOI: 10.1002/cam4.5732. View

Berardi G, Chou J, Gonen M, Balachandran V, Drebin J, Jarnagin W . A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases. Ann Surg Oncol. 2023; 30(5):2820-2827. PMC: 10089972. DOI: 10.1245/s10434-023-13113-2. View

Margonis G, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D . Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. JAMA Surg. 2015; 150(8):722-9. PMC: 4696064. DOI: 10.1001/jamasurg.2015.0313. View

Beppu T, Yamamura K, Sakamoto K, Honda G, Kobayashi S, Endo I . Validation study of the JSHBPS nomogram for patients with colorectal liver metastases who underwent hepatic resection in the recent era - a nationwide survey in Japan. J Hepatobiliary Pancreat Sci. 2022; 30(5):591-601. DOI: 10.1002/jhbp.1256. View

10.

Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J . Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(1):10-32. DOI: 10.1016/j.annonc.2022.10.003. View

11.

Oba M, Hasegawa K, Matsuyama Y, Shindoh J, Mise Y, Aoki T . Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Ann Surg Oncol. 2014; 21(6):1817-24. DOI: 10.1245/s10434-014-3504-1. View

12.

Margonis G, Sasaki K, Gholami S, Kim Y, Andreatos N, Rezaee N . Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg. 2018; 105(9):1210-1220. PMC: 7988484. DOI: 10.1002/bjs.10838. View

13.

Takeda Y, Mise Y, Takahashi Y, Ito H, Inoue Y, Yoshioka R . Limited Prognostic Value of KRAS in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg Oncol. 2021; 29(4):2383-2391. DOI: 10.1245/s10434-021-11015-9. View

14.

Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H . Liver resection for colorectal metastases: the third hepatectomy. Ann Surg. 2003; 238(6):871-83. PMC: 1356169. DOI: 10.1097/01.sla.0000098112.04758.4e. View

15.

Yan T, Sim J, Black D, Niu R, Morris D . Systematic review on safety and efficacy of repeat hepatectomy for recurrent liver metastases from colorectal carcinoma. Ann Surg Oncol. 2007; 14(7):2069-77. DOI: 10.1245/s10434-007-9388-6. View

16.

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12):1208-15. DOI: 10.1016/S1470-2045(13)70447-9. View

17.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

18.

Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y . A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2011; 19(1):72-84. DOI: 10.1007/s00534-011-0460-z. View

19.

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371(9617):1007-16. PMC: 2277487. DOI: 10.1016/S0140-6736(08)60455-9. View

20.

Hoppener D, Nierop P, van Amerongen M, Olthof P, Galjart B, van Gulik T . The Disease-Free Interval Between Resection of Primary Colorectal Malignancy and the Detection of Hepatic Metastases Predicts Disease Recurrence But Not Overall Survival. Ann Surg Oncol. 2019; 26(9):2812-2820. PMC: 6682566. DOI: 10.1245/s10434-019-07481-x. View